The effect of a series of anti-cancer drugs on plasma cholinesterase activity.
D000970:Antineoplastic Agents / Q000494:pharmacology*; D001565:Benzoates; D002794:Choline; D002800:Cholinesterase Inhibitors / Q000494:pharmacology*; D002802:Cholinesterases / Q000097:blood*; D003520:Cyclophosphamide / Q000494:pharmacology; D003609:Dactinomycin / Q000494:pharmacology; D005467:Floxuridine / Q000494:pharmacology; D005472:Fluorouracil / Q000494:pharmacology; D006801:Humans; D006868:Hydrolysis; D066298:In Vitro Techniques; D008466:Mechlorethamine / Q000494:pharmacology; D011343:Procaine; D013852:Thiotepa / Q000494:pharmacology; D014265:Triethylenemelamine / Q000494:pharmacology; D014747:Vinblastine / Q000494:pharmacology; D014750:Vincristine / Q000494:pharmacology
D000970:Antineoplastic Agents; D001565:Benzoates; D002800:Cholinesterase Inhibitors; D005467:Floxuridine; D003609:Dactinomycin; D011343:Procaine; D008466:Mechlorethamine; D014750:Vincristine; D014747:Vinblastine; D003520:Cyclophosphamide; D013852:Thiotepa; D002802:Cholinesterases; D014265:Triethylenemelamine; D002794:Choline; D005472:Fluorouracil